The clinical evaluation committee in a large multicenter phase 3 trial of drotrecogin alfa (activated) in patients with severe sepsis (PROWESS): Role, methodology, and results

OBJECTIVEIn the multinational PROWESS trial, drotrecogin alfa (activated) significantly reduced mortality rate in patients with severe sepsis compared with placebo. The use of large multiple-center trials can potentially complicate interpretation of results in severe sepsis populations because of va...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Critical care medicine 2003-09, Vol.31 (9), p.2291-2301
Hauptverfasser:	Dhainaut, Jean-François, Laterre, Pierre-François, LaRosa, Steven P, Levy, Howard, Garber, Gary E, Heiselman, Darell, Kinasewitz, Gary T, Light, R Bruce, Morris, Peter, Schein, Roland, Sollet, Jean-Pierre, Bates, Becky M, Utterback, Barbara G, Maki, Dennis
Format:	Artikel
Sprache:	eng
Schlagworte:	Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy Anti-Infective Agents - administration & dosage APACHE Bacteremia - drug therapy Bacteremia - microbiology Bacteremia - mortality Biological and medical sciences Confidence Intervals Dose-Response Relationship, Drug Double-Blind Method Drug Administration Schedule Emergency and intensive care: infection, septic shock Female Follow-Up Studies Gram-Negative Bacterial Infections - diagnosis Gram-Negative Bacterial Infections - drug therapy Gram-Negative Bacterial Infections - mortality Gram-Positive Bacterial Infections - diagnosis Gram-Positive Bacterial Infections - drug therapy Gram-Positive Bacterial Infections - mortality Humans Intensive care medicine Intensive Care Units Male Medical sciences Probability Protein C - administration & dosage Recombinant Proteins - administration & dosage Risk Assessment Severity of Illness Index Survival Analysis Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!